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Estimation of Significance Thresholds for Genomewide
Association Scans
Frank Dudbridge and Arief Gusnanto
MRC Biostatistics Unit, Institute for Public Health, Cambridge, United Kingdom
The question of what significance threshold is appropriate for genomewide association studies is somewhat unresolved.
Previous theoretical suggestions have yet to be validated in practice, whereas permutation testing does not resolve a
discrepancy between the genomewide multiplicity of the experiment and the subset of markers actually tested. We used
genotypes from the Wellcome Trust Case-Control Consortium to estimate a genomewide significance threshold for the
UK Caucasian population. We subsampled the genotypes at increasing densities, using permutation to estimate the nominal
P-value for 5% family-wise error. By extrapolating to infinite density, we estimated the genomewide significance threshold
to be about 7.2 108. To reduce the computation time, we considered Patterson’s eigenvalue estimator of the effective
number of tests, but found it to be an order of magnitude too low for multiplicity correction. However, by fitting
a Beta distribution to the minimum P-value from permutation replicates, we showed that the effective number is a
useful heuristic and suggest that its estimation in this context is an open problem. We conclude that permutation is still
needed to obtain genomewide significance thresholds, but with subsampling, extrapolation and estimation of an
effective number of tests, the threshold can be standardized for all studies of the same population. Genet. Epidemiol. 32:
227–234, 2008. r 2008 Wiley-Liss, Inc.
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INTRODUCTION
The question of what strength of evidence
should be considered significant has yet to be fully
resolved in genetic association analysis. On the
one hand, multiple testing issues arise in most
studies, whether based on candidate genes or
genomewide scans, with attendant issues of how
to quantify the multiplicity, what error rate to
control and which method to use [Manly
et al., 2004]. On the other hand, even under strong
control of the type-1 error, many associations have
not been replicated and are thought to have been
false positives. This disappointing aspect can
be attributed to the use of traditional thresholds
of significance, even after adjustment for multiple
testing, which reflect over-optimistic prior belief
in the tested hypotheses [Ioannidis, 2005]. In
the current period of genomewide association
scans, using a dense but incomplete panel of
single nucleotide polymorphism (SNP) markers
[Barrett and Cardon, 2006], such considerations take
on greater importance owing to the high profile and
cost of these studies.
Here we discuss some aspects of assessing
significance in genomewide scans, and estimate a
genomewide significance threshold for the UK
Caucasian population using data from the recently
completed Wellcome Trust Case-Control Consortium
[2007] (WTCCC) study. We allow for a potentially
saturated dense marker panel to distinguish the
genomewide multiplicity of the experiment from the
set of markers actually tested. This approach has a
long history in linkage analysis [Morton, 1955;
Lander and Kruglyak, 1995] but has generally
not been taken up in association mapping. Our
approach brings together previous ideas based on
the hypothesized extent of multiplicity in the
genome, with emerging marker data that allow this
multiplicity to be estimated.
The multiple testing problem arises because, if
many hypotheses are tested simultaneously, some
test statistics will be surprisingly extreme, even if no
associations exist. Multiple test procedures are
designed to exercise control over the entire set of
hypotheses, to prevent study-wide conclusions
being drawn that could be attributed to chance
alone. The family-wise error rate (FWER) is the
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probability of committing at least one type-1 error,
and may be controlled in the weak sense, when all
null hypotheses are true, or in the strong sense,
when any subset of hypotheses is true [Hochberg
and Tamhane, 1987]. More recently, the false
discovery rate (FDR) [Benjamini and Hochberg,
1995] and variations [Efron and Tibshirani, 2002]
have gained support, as we may tolerate some type-
1 errors so long as they are a small proportion of the
rejected hypotheses. Bayes factors have also been
advocated to quantify the strength of evidence in
each test [WTCCC, 2007]. Here we are not concerned
with discriminating between different error mea-
sures, but note that when the number of false
hypotheses is small, control of the standard FDR is
close to weak control of the FWER [Benjamini and
Hochberg, 1995]. Moreover, in this situation strong
control of FWER is close to the best methods for
weak control [Dudbridge and Koeleman, 2003]. Also
when the evidence is strong and the power is high,
there is a strong correlation between the Bayes factor
and the P-value [Thomas and Clayton, 2004]. In
what follows we will therefore consider strong
control of FWER by the Bonferroni method, or its
permutational equivalent [Westfall and Young,
1993], as a conservative baseline to which other
methods can be calibrated.
The first well-known suggestion for a genome-
wide significance threshold for association was by
Risch and Merikangas [1996]. They assumed a gene-
centric study of 100,000 genes, with an average of
five SNPs tested in each gene, leading to a
Bonferroni significance threshold of 5 108 for
one-sided tests of each allele. Although these
assumptions are now obsolete, this threshold has
proved remarkably durable, and valid in the sense
that, to our knowledge, no association reported as
exceeding it has proved a false positive. Another
estimate for a gene-centric study assumed 30,000
genes, with 10 genes having normally distributed
effects, leading to a threshold of 1106 for a gene-
wide test [Clayton, 2003; Thomas and Clayton, 2004].
More recently, attention has shifted from gene-
centric studies to genomewide scans of anonymous
SNPs. In this context the International HapMap
Consortium [2005] used permutation tests of high-
density genotypes in 10 genomic regions to estimate
an ‘‘effective number of independent tests’’ of 150
per 500 kbp. Scaling up to a 3 Gb genome suggests a
significance threshold of 5.5 108 for two-sided
tests of SNPs. The only threshold that has to date
been rigorously applied to more than one scan is that
of the WTCCC [2007]. Assuming 106 independent
regions of the genome, 10 disease-causing genes and
average power 50% to detect an associated gene,
posterior odds of 10:1 in favour of association would
be achieved by a nominal P-value of 5 107.
With genomewide SNP data now available, per-
mutation tests have been suggested to obtain
appropriately adjusted P-values [Churchill and
Doerge, 1994]. The difficulty is that standard
permutation tests only account for the markers
actually tested, whereas the multiplicity spans the
whole genome. This is important because although
P-values are the usual output of classical tests, the
real quantities of interest are the posterior odds for
association or the closely related false-positive
reporting probability [Wacholder et al., 2004] and
positive predictive value [Ioannidis, 2005]. For a
class of tests significant when a statistic T4t, the
posterior odds may be expressed in terms of the
prior odds as
PrðH1jT4tÞ
PrðH0jT4tÞ
¼ PrðT4tjH1Þ
PrðT4tjH0Þ
PrðH1Þ
PrðH0Þ
¼ 1  b
a
PrðH1Þ
PrðH0Þ
ð1Þ
where a, Beta are the type-1 and type-2 error rates of
the test, respectively. Consideration of the prior odds
is intrinsic to the Bayesian perspective, but it is also
implicit in frequentist testing, if it is to be used
responsibly.
Suppose one chose a single SNP at random, tested
for association to a trait and obtained a P-value of
exactly 0.05. As one test was performed, no correc-
tion for multiplicity is required, and from the
frequentist perspective one may reject the hypoth-
esis that no SNP is associated and invoke the closure
principle to claim that the tested SNP is associated
[Hochberg and Tamhane, 1987]. However, this is
clearly absurd, as there was almost no prior reason
to expect an association. In fact at standard error
rates of a5 0.05 and Beta5 0.2, one would require
prior odds of 2:1 against to obtain posterior odds of
8:1 in favor of association, or prior odds of evens to
obtain posterior odds of 16:1. Usage of standard
frequentist thresholds is only justified when the
prior odds are in this order of magnitude, say
between evens and 10:1 against.
Of course, tested SNPs are not chosen randomly,
but the relative lack of success of candidate–gene
association studies, apparently well powered for
nominal significance, suggests that the prior odds
have generally been exaggerated [Ioannidis, 2005].
However, a genomewide scan, for which SNPs are
provided by a commercial supplier of genotyping
chips, is in a sense little different from a random
selection, except that the prior odds are substantially
shortened. Yet, unless the chip has complete cover-
age of the genome, there remains a discrepancy
between the number of SNPs tested and the actual
prior odds of any SNP being associated. Our view is
that a responsible use of P-value thresholds must
reflect the multiplicity of the whole genome, rather
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than of the set of SNPs tested. This is in line with the
previous approaches [International HapMap Con-
sortium, 2005; WTCCC, 2007] and facilitates the
comparison of results between different marker
panels as well as those obtained by imputation
methods that estimate the genotypes of markers not
directly typed [Marchini et al., 2007]. However,
permutation methods for multiple test correction
only take account of the genotyped markers, and use
of these methods with standard thresholds may,
potentially, lead to over-optimistic interpretation of
significant results.
Given these difficulties the Bayesian perspective
seems attractive, but now one is faced with
quantifying the prior odds. In fact, there is now
sufficient background knowledge to allow this to be
done rather objectively [Wachholder et al., 2004;
Wakefield, 2007], and it can be argued that the major
obstacle to widespread use of this paradigm is
convention. Nevertheless, these approaches can only
be validated through experience, and as a rule of
thumb, naı¨ve Bayesian analysis should result in
similar conclusions to a frequentist analysis, if both
are well calibrated.
With these arguments in mind, we therefore
consider estimation of a frequentist P-value thresh-
old that accounts for the multiplicity of the whole
genome and can be used as a baseline for calibrating
other approaches. We consider two approaches to
estimating this threshold, accounting for the correla-
tion within the genome: one based on a permutation
scheme, and the other using linear algebra to
estimate an effective number of tests directly from
genotype data [Patterson et al., 2006]. We apply both
methods to genotypes released by the WTCCC,
extrapolating the results to complete saturation to
obtain a genomewide threshold. We conclude by
discussing some implications of these results in the
light of the WTCCC and other studies.
METHODS
DATA
We used genotypes from the two control cohorts in
the WTCCC [2007] study to sample the UK
Caucasian population without disease association.
Data were available for 1,485 blood donors (the
National Blood Service (NBS) sample) and 1,504
members of the 1958 British Birth Cohort. We
considered the two samples, both separately and
combined. We analyzed the autosomal data only, for
which genotypes were available for 490,032 SNPs on
the commercial release of the GeneChip 500 K
Affymetrix array. We excluded genotypes whose
posterior probability according to the CHIAMO
algorithm [WTCCC, 2007] was less than 0.95: this
excluded 2.3% of genotypes in the NBS and 1% in
the 58BC samples. In order to ensure that all test
statistics had the w2 distribution under the null
hypothesis, we only used SNPs for which there were
at least 10 subjects having each genotype, leaving
334,773 SNPs in the NBS, 335,331 in the 58BC and
359,491 in the combined samples.
PERMUTATION TEST
We estimated a genomewide significance thresh-
old using a permutation procedure. We randomly
designated half the sample ‘‘cases’’ and the other
half ‘‘controls’’ and calculated the Armitage test of
trend for differences in genotype frequency.
P-values for all SNPs were sorted and the 1,000
smallest were recorded. This procedure was
repeated 10,000 times.
The 5% quantile point of the minimum P-value
represents the genomewide significance threshold at
this marker density. To extrapolate to complete
saturation, we randomly subsampled the SNPs over
a range of lower densities by equivalently subsam-
pling the sorted P-values independently for each
permutation replicate. We used a uniform grid of 100
marker densities, and at each density the 5% point of
the minimum P-value was recorded. We repeated
the subsampling 100 times at each density and used
the mean 5% point in subsequent analysis. At low
densities, the SNPs are expected to be independent;
hence, according to the Bonferroni law the 5% point
is inversely proportional to the number of SNPs. At
high densities we expect the 5% point to converge to
an asymptote, reflecting the significance threshold
for the whole genome.
Denote the proportion of SNPs subsampled by
xi; i5 1,2,y, where xioxiþ1 and xi are relative to the
total number of SNPs used in the estimation. Denote
the corresponding 5% quantile points yi. It follows
that the effective number of independent tests
defined by
mi ¼
0:05
yi
ð2Þ
should be proportional to xi when xi is small and
should converge to an asymptote as xi grows large.
To obtain these properties, we fit the Monod
function to (xi,mi):
fðx; m; kÞ ¼ mx
kþ x : ð3Þ
This model is not claimed to be exact, but it has been
found to fit data well in applications such as
modeling population growth with limited resources
[e.g. Cohen and Gu¨rtler, 2001]. The parameters of
this model are m, the limit as x-N, and k, the half-
saturation parameter representing the value of x for
which fðxÞ ¼ m=2: We estimated the parameters by
least squares to give the genomewide significance
229Genomewide Significance Thresholds
Genet. Epidemiol.
threshold as
a^genome ¼
0:05
m^
: ð4Þ
We used a non-parametric bootstrap to estimate
confidence intervals for a^genome: We resampled the
minimum P-values with replacement from the
permutation replicates, and for each resampling we
subsampled SNPs, fitted the Monod function and
calculated a^genome: We estimated 95% confidence
intervals for m^; k^ and a^genome from 1,000 bootstrap
samples.
EFFECTIVE NUMBER OF TESTS
Permutation procedures are time consuming, and
an attractive alternative is to estimate an effective
number of independent tests directly from the
genotype correlation matrix. A moment-based esti-
mator was recently proposed by Patterson et al.
[2006] based on the eigenvalues of the correlation
matrix. This estimator has good properties in the
context of detecting population structure, but we
wished to see whether it is equally useful for
correcting multiplicity. Let
X ¼ 1=nMM0 ð5Þ
where n is the number of markers and M is a
normalized matrix of genotypes with one row per
subject and one column per marker [for details, see
Patterson et al., 2006]. Denoting the eigenvalues of X
by l1,y,lm, where m is the number of subjects, the
effective number of tests is estimated by
nP ¼
ðmþ 1ÞðPi liÞ2
ððm 1ÞPi l2i Þ  ðPi liÞ2 : ð6Þ
As for the permutation test, we estimated nP for a
grid of subsampling densities. We calculated nP for
each chromosome and summed to obtain a genome-
wide estimate.
BETA DISTRIBUTION
If there really is an effective number of indepen-
dent tests nE, then the minimum P-value should
follow a Beta distribution with parameters (1,nE), as
[Sˇida´k, 1967]
PrðminP  aÞ ¼ 1  ð1  aÞnE : ð7Þ
We fitted the Beta distribution to the minimum P-
value of the permutation replicates, with the first
parameter set to 1 and also with both parameters
free. This would allow us to test whether the
minimum P-value is consistent with an effective
number of independent tests, by testing whether the
first parameter is 1 [Dudbridge and Koeleman,
2004], and whether Patterson’s estimator is accurate,
by testing whether nP5 nE. The moment estimators
for the parameters of the Beta (a,b) distribution are
a^ ¼ x xð1  xÞ
s2
 1
 
ð8Þ
b^ ¼ ð1  xÞ xð1  xÞ
s2
 1
 
; ð9Þ
where x and s2 are the sample mean and variance of
observations, respectively. When a is set to 1, the
moment estimate of b is
b^ ¼ 1  x
x
: ð10Þ
We used the moment estimates as starting points for
numerical maximum likelihood estimation, using
the optim function in R.
RESULTS
For the permutation procedure, Table I gives the
estimated asymptote m^; half-saturation parameter k^
and genomewide significance threshold a^genome for
the NBS and 58BC samples separately and com-
bined. It is clear that the estimates are similar for the
separate cohorts, so they may be combined to give
greater precision. Figure 1(a) shows the threshold for
5% family-wise error plotted as a function of marker
density for the combined samples. Figure 1(b) shows
the corresponding effective numbers of tests to-
gether with the fitted Monod function. The curve is a
good fit, but it is clear that it is not at its asymptote at
the current density, although some curvature is
apparent when compared with the linear regression
line. The estimated asymptote was m^ ¼ 651; 550;
which increases to 693,138 assuming that the
autosomes comprise 94% of the total genome length.
This gives our estimated genomewide significance
threshold as
a^genome ¼ 7:2  108 ð11Þ
with 95% bootstrap confidence interval (6.3–8.9)
 108.
TABLE I. Fitted asymptotes m^ and half-saturation
parameters k^ of Monod functions
NBS 58BC NBS158BC
m^ ( 106) 5.29 (4.25–6.07) 4.96 (4.14–5.70) 6.52 (5.26–7.43)
k^ 1.73 (1.35–1.92) 1.58 (1.28–1.82) 1.88 (1.47–2.11)
a^genome ( 108) 8.9 (7.7–11.3) 9.5 (8.3–11.4) 7.2 (6.3–8.9)
Estimated genomewide significance thresholds a^genome are calcu-
lated as 0:047=m^, assuming that the autosomes comprise 94% of the
total genome length.
NBS: National Blood Service.
58BC: 1958 British Birth Cohort.
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The half-saturation parameter was estimated as
k^ ¼ 1:88 (1.47–2.11), indicating that at about twice the
current number of markers, only half the total
multiplicity will be accounted for. This does not
mean that current marker panels have insufficient
coverage, rather that permutation correction based
only on typed markers may be too optimistic; we
return to this point in the Discussion.
For Patterson’s estimator, Figure 2 shows the 5%
family-wise error threshold and effective number of
tests compared to the permutation procedure, over a
uniform grid of 20 marker densities. There is clearly
a wide discrepancy and at the current marker
density the estimate is an order of magnitude too
low: 33,279 compared to 227,838 for the permutation
scheme, even though the latter allowed for correla-
tion between chromosomes. The use of P-value
thresholds based on this estimator will therefore
inflate the false-positive rate. This result is not
entirely surprising, as we have previously noted
that the effective number of tests, if it exists, is a
function of both the significance threshold and also
of the type of analysis [Dudbridge and Koeleman,
2004]. Thus, it is not unexpected that an estimator
Fig. 1. (a) Significance threshold as a function of marker density in combined NBS and 58BC sample from permutation procedure. At
current density (359K single nucleotide polymorphisms typed) the significance threshold is about 2.2 107. The dotted line shows the
estimated asymptote of 7.2 108. (b) Fitted Monod function to the effective number of tests associated with the significance threshold.
At infinite density the number of tests is estimated at 693,138 giving the asymptote in (a).
Fig. 2. (a) Significance thresholds from permutation procedure and Patterson’s estimate of the effective number of tests. At current
marker density, the estimates differ by an order of magnitude. (b) The effective numbers of tests based on the permutation procedure
and Patterson’s estimator. At current marker density, Patterson’s estimate is too low (33,279) compared to that of the permutation
procedure (227,838).
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that works well for analysis of population structure
is not accurate for Bonferroni corrections.
However, the fitted Beta distributions do suggest
that an effective number of tests exists and could be
useful. Figure 3 compares the empirical distribution
of the minimum P-value for the combined samples,
to the fitted Beta (1,nE) and Beta (a,b) distributions.
Both Beta distributions are clearly a good fit to the
observed data. The maximum likelihood estimate
a^ ¼ 0:97 is close to 1; the null hypothesis of equality
was formally rejected (P5 0.01), but this is not
surprising given our high power to reject strict
equality, and the test was not significant in the
separate NBS and 58BC samples. This is in line with
our results on an early version of HapMap [Dud-
bridge and Koeleman, 2004], in which the test of
equality was extremely significant, suggesting that
the effective number of tests is a worse fit at higher
marker densities. The effective numbers of tests
were similar to those estimated from the permuta-
tion procedure for both cohorts (Table II).
DISCUSSION
To set a baseline for multiplicity adjustments, we
have estimated a genomewide significance thresh-
old of about 7.2 108 for two-sided tests of single
SNPs in the UK Caucasian population. This is
similar to the threshold suggested by the Interna-
tional HapMap Consortium [2005], which is reassur-
ing as that study took a complementary approach.
They extrapolated near-saturated local regions to the
whole genome, whereas we took sparse data over
the whole genome and extrapolated to complete
saturation. Nevertheless, our estimate is not precise:
in contrast to previous approaches we are able to
report a confidence interval, which reflects the
variation due to the finite number of permutations
and random subsampling of SNPs. The half-satura-
tion parameter is about twice the current number of
markers, suggesting that the current marker density
reflects less than half the total multiplicity in the
genome. This does not imply that the marker panels
have insufficient coverage, for it has been estimated
that up to 80% of the variation in the genome is
correlated to current panels [Barrett and Cardon,
2006]. Rather, the statistical cost of obtaining all the
remaining information is high in relation to what is
already available, and the number of markers that
give near-complete saturation could be much lower.
Nevertheless, it is clear that denser chips are needed
to obtain more accurate estimates of significance
thresholds, and it is meanwhile prudent to treat
these thresholds as no more than informal guide-
lines.
We have relied on permutation testing to estimate
significance thresholds, as this preserves the correla-
tion structure in the sample. Similar results from the
NBS and 58BC samples suggest that sampling
variation in the correlation structure is negligible.
Permutation tests are time consuming, and a con-
venient alternative is to estimate an effective number
of tests from the genotype correlation matrix. Our
results from fitting Beta distributions indicate that
such an effective number can be found, at least at the
current density, but we found that Patterson’s
moment estimator was an order of magnitude too
low for correcting the minimum P-value. It is an
open problem to directly estimate the appropriate
correction for minimum P from genotype data.
The WTCCC study is widely held to have been a
success, yet the P-value threshold used by that study
is an order of magnitude higher than our estimate.
Why were there not many false positives? One
reason is that the rationale for their choice of 5 107
was based on prior odds for a region being
associated, rather than a single SNP, and adjustment
towards single SNP tests could bring the estimate
closer to ours. Another practical aspect is that, for
reasons of quality control, the study only followed
up regions with multiple SNPs showing evidence of
association. A formal combination of evidence from
neighboring SNPs could produce stronger P-values
exceeding those of the single SNPs. Finally, of the 21
Fig. 3. Quantile–quantile plot comparing fitted Beta distribu-
tions with minimum P-values from permutation replicates.
TABLE II. Estimated effective numbers of tests
corresponding to the 5% point of the minimum P-value,
from fitting Beta (1,nE) distribution and from
permutation scheme
NBS 58BC NBS158BC
Beta Distribution 195,469 199,334 216,457
Permutations 195,539 193,505 227,838
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single-SNP associations reported by the study, only
three had P-values less than 5 107 but greater
than 8 108, so that chance may have played a role.
Nevertheless, at the time of writing the WTCCC
reported successful replication of 10 associations
from 11 attempts. Assuming that the failed replica-
tion was a false positive, this does not constitute
success by classical measures: a family-wise type-1
error occurred, and the false discovery proportion
was nearly 10%. Only the Bayesian interpretation
that posterior odds for association are 10:1 seems
satisfactory. Therefore, the fact that the study is
considered a success throws light on how multi-
plicity is interpreted in practice. Family-wise error is
too conservative for rejecting individual hypotheses,
and the FDR can be higher than traditional type-1
error rates. Posterior odds of 10:1 seem acceptable,
which justifies the use of Po0.05 for hypothesis
testing provided that the prior odds are close to
evens. Such a prior is reasonable for genomewide
association scans as long as the whole genome is
considered rather than limited subsets of markers.
If family-wise error is too conservative, then do we
need a genomewide significance threshold? We have
argued that for the global null that no locus is
associated, strong control of FWER is an acceptable
proxy for weak control, FDR or Bayes factor
approaches. Thus, if no locus is genomewide
significant, we may conclude that no associations
have been found, whereas if some loci are genome-
wide significant, other approaches can be used to
decide which should be declared associated. It may
be argued that the global null is not of interest, as the
entire study is predicated on it being false. However,
we feel that a significant global test is evidence that
there is sufficient signal in the data to distinguish
true from false positives. Given the uncertainty over
what thresholds should be applied, the common
pragmatic approach is to follow up associations in
rank order, and this can be justified by a significant
global test. Estimation of a genomewide significance
threshold gives a baseline that can justify both
pragmatic and principled approaches to selecting
loci for follow-up.
We have only considered common SNPs repre-
sented on the GeneChip 500k array, and moreover
only those for which the w2-distribution is accurate.
Mathematically this is not a serious problem:
provided uniformly distributed P-values can be
obtained, our approach applies to any variants.
However, it is possible that rare variants follow a
different linkage disequilibrium (LD) structure,
because they are likely to be younger or under
different selection pressures than common variants.
Our results strictly apply only to common variation,
and the implicit assumption that common variation
occurs at arbitrarily fine scales may be unreasonably
conservative. The similarity of our estimate to that of
the International HapMap Consortium [2005] sug-
gests that this assumption has not had a major
impact on our results.
We have also made no assumption about which
SNPs are more likely to be associated. One com-
monly held view is that non-synonymous or other
coding SNPs are more likely to be associated than
random SNPs, but this view is by no means
universal, and the evidence is only now accruing
through the first generation of scans. Furthermore,
in a linkage disequilibrium scan of tag SNPs, it is
harder to distinguish functional from non-functional
SNPs. Another view is that SNPs in longer blocks of
LD are more likely to be associated [Pe’er et al.,
2006]. However, in a scan of randomly chosen SNPs,
such as those considered here, this prior is likely to
be attenuated by the fact that longer blocks of LD are
likely to contain more genotyped SNPs [I. Pe’er,
Personal Communication]
Strictly speaking, our results apply only to the UK
Caucasian population, but we should expect similar
results in other outbred populations of the same age.
The HapMap data could be used to apply our
methods to African and Asian populations, using a
denser map of SNPs, but because of the small
sample size we are not confident that the genome-
wide distribution of statistics from permutation
samples is the same as would be applicable to a
large sample. We therefore restricted our study to a
large sample that has been used for a real genome-
wide association scan.
We have shown that previous proposals for
genomewide significance have been in the right
order of magnitude. It seems clear that, in a Western
population, any P-value less than say 5 108 can be
regarded as convincingly significant. We rely on
permutation testing to estimate significance thresh-
olds, but these should be adjusted to reflect the
genomewide multiplicity. Estimation of an effective
number of tests remains an open problem but one
which has potential to considerably reduce the
computational burden. The next generation of
genotyping chips should allow more accurate
estimation of significance thresholds with applica-
tion to a wider range of genomic variation.
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